Skip to content
1887

Journal of General Virology header logo Journal of General Virology

Volume 97, Issue 5

Generation of a neutralization-resistant CCR5 tropic simian/human immunodeficiency virus (SHIV-MK38) molecular clone, a derivative of SHIV-89.6 No Access

Abstract

Previously, we reported that a new genetically diverse CCR5 (R5) tropic simian/human immunodeficiency virus (SHIV-MK38) adapted to rhesus monkeys became more neutralization resistant to SHIV-infected plasma than did the parental SHIV-KS661 clone. Here, to clarify the significance of the neutralization-resistant phenotype of SHIV in a macaque model, we initially investigated the precise neutralization phenotype of the SHIVs, including SHIV-MK38 molecular clones, using SHIV-MK38-infected plasma, a pooled plasma of human immunodeficiency virus (HIV)-infected individuals, soluble CD4 and anti-HIV-1 neutralizing mAbs, the epitopes of which were known. The results show that SHIV-KS661 had tier 1 neutralization sensitivity, but monkey-adapted R5 tropic SHIV-MK38 acquired neutralization resistance similar to that of tier 2 or 3 as a clone virus. Sequence analysis of the gene suggested that the neutralization-resistant phenotype of SHIV-MK38 was acquired by conformational changes in Env associated with the net charge and potential -linked glycosylation sites. To examine the relationship between neutralization phenotype and stably persistent infection in monkeys, we performed rectal inoculation experiments using a SHIV-MK38 molecular clone. The results showed that one of three rhesus monkeys exhibited durable infection with a plasma viral load of 10 copies ml despite the high antibody responses that occurred in the host. Whilst further improvements are required in the development of a challenge virus, it will be useful to generate a neutralization-resistant R5 tropic molecular clone of the SHIV-89.6 lineage commonly used for vaccine development – a result that can be used to explore the foundation of AIDS pathogenesis.

  • Received:
  • Accepted:
  • Published Online:
© 2016 The Authors
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000421
2016-05-01
2026-03-13

Metrics

Loading full text...

Full text loading...

References

  1. Boyd D. F., Peterson D., Haggarty B. S., Jordan A. P., Hogan M. J., Goo L., Hoxie J. A., Overbaugh J. 2015; Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer. J Virol 89:894–907 [View Article][PubMed]
     [Google Scholar]
  2. Buchbinder S. P., Mehrotra D. V., Duerr A., Fitzgerald D. W., Mogg R., Li D., Gilbert P. B., Lama J. R., Marmor M., other authors. 2008; Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881–1893 [View Article][PubMed]
     [Google Scholar]
  3. Cardozo T., Kimura T., Philpott S., Weiser B., Burger H., Zolla-Pazner S. 2007; Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses 23:415–426 [View Article][PubMed]
     [Google Scholar]
  4. Casimiro D. R., Wang F., Schleif W. A., Liang X., Zhang Z.-Q., Tobery T. W., Davies M.-E., McDermott A. B., O'Connor D. H., other authors. 2005; Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J Virol 79:15547–15555 [View Article][PubMed]
     [Google Scholar]
  5. DuBridge R. B., Tang P., Hsia H. C., Leong P. M., Miller J. H., Calos M. P. 1987; Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7:379–387 [View Article][PubMed]
     [Google Scholar]
  6. Eda Y., Takizawa M., Murakami T., Maeda H., Kimachi K., Yonemura H., Koyanagi S., Shiosaki K., Higuchi H., other authors. 2006; Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. J Virol 80:5552–5562 [View Article][PubMed]
     [Google Scholar]
  7. Etemad-Moghadam B., Sun Y., Nicholson E. K., Fernandes M., Liou K., Gomila R., Lee J., Sodroski J. 2000; Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo . J Virol 74:4433–4440 [View Article][PubMed]
     [Google Scholar]
  8. Fouchier R. A., Groenink M., Kootstra N. A., Tersmette M., Huisman H. G., Miedema F., Schuitemaker H. 1992; Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 66:3183–3187[PubMed]
     [Google Scholar]
  9. Francica J. R., Sheng Z., Zhang Z., Nishimura Y., Shingai M., Ramesh A., Keele B. F., Schmidt S. D., Flynn B. J., other authors. 2015; Analysis of immunoglobulin trascripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization. Nat Commun 6:6565 [View Article]
     [Google Scholar]
  10. Fukazawa Y., Miyake A., Ibuki K., Inaba K., Saito N., Motohara M., Horiuchi R., Himeno A., Matsuda K. other authors 2008; Small intestine CD4+ T cells are profoundly depleted during acute simian-human immunodeficiency virus infection, regardless of viral pathogenicity. J Virol 82:6039–6044 [View Article][PubMed]
     [Google Scholar]
  11. Gardner M. R., Kattenhorn L. M., Kondur H. R., von Schaewen M., Dorfman T., Chiang J. J., Haworth K. G., Decker J. M., Alpert M. D., other authors. 2015; AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519:87–91 [View Article][PubMed]
     [Google Scholar]
  12. Gautam R., Nishimura Y., Lee W. R., Donau O., Buckler-White A., Shingai M., Sadjadpour R., Schmidt S. D., LaBranche C. C., other authors. 2012; Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIVAD8 in rhesus macaques: implications for use in vaccine studies. J Virol 86:8516–8526 [View Article][PubMed]
     [Google Scholar]
  13. Hsu M., Harouse J. M., Gettie A., Buckner C., Blanchard J., Cheng-Mayer C. 2003; Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120. J Virol 77:989–998 [View Article][PubMed]
     [Google Scholar]
  14. Inaba K., Fukazawa Y., Matsuda K., Himeno A., Matsuyama M., Ibuki K., Miura Y., Koyanagi Y., Nakajima A., other authors. 2010; Small intestine CD4+ cell reduction and enteropathy in simian/human immunodeficiency virus KS661-infected rhesus macaques in the presence of low viral load. J Gen Virol 91:773–781 [View Article][PubMed]
     [Google Scholar]
  15. Javaherian K., Langlois A. J., Schmidt S., Kaufmann M., Cates N., Langedijk J. P., Meloen R. H., Desrosiers R. C., Burns D. P., Bolognesi D. P. 1992; The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 89:1418–1422 [View Article][PubMed]
     [Google Scholar]
  16. Kawamura M., Ishizaki T., Ishimoto A., Shioda T., Kitamura T., Adachi A. 1994; Growth ability of human immunodeficiency virus type 1 auxiliary gene mutants in primary blood macrophage cultures. J Gen Virol 75:2427–2431 [View Article][PubMed]
     [Google Scholar]
  17. Kwong P. D., Mascola J. R., Nabel G. J. 2013; Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol 13:693–701 [View Article][PubMed]
     [Google Scholar]
  18. Letvin N. L., Mascola J. R., Sun Y., Gorgone D. A., Buzby A. P., Xu L., Yang Z.-Y., Chakrabarti B., Rao S. S. other authors 2006; Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312:1530–1533 [View Article][PubMed]
     [Google Scholar]
  19. Matsuda K., Inaba K., Fukazawa Y., Matsuyama M., Ibuki K., Horiike M., Saito N., Hayami M., Igarashi T., Miura T. 2010 In vivo analysis of a new R5 tropic SHIV generated from the highly pathogenic SHIV-KS661, a derivative of SHIV-89.6. Virology 399:134–143 [View Article][PubMed]
     [Google Scholar]
  20. Mehandru S. 2007; The gastrointestinal tract in HIV-1 infection: questions, answers, and more questions!. The PRN Notebook 12 http://www.prn.org/index.php/progression/article/hiv_1_gastrointestinal_galt_267
     [Google Scholar]
  21. Miyake A., Ibuki K., Enose Y., Suzuki H., Horiuchi R., Motohara M., Saito N., Nakasone T., Honda M., other authors. 2006; Rapid dissemination of a pathogenic simian/human immunodeficiency virus to systemic organs and active replication in lymphoid tissues following intrarectal infection. J Gen Virol 87:1311–1320 [View Article][PubMed]
     [Google Scholar]
  22. Moore J. P., Cao Y., Qing L., Sattentau Q. J., Pyati J., Koduri R., Robinson J., Barbas C. F. III Burton D R & Ho D D 1995; Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 69:101–109[PubMed]
     [Google Scholar]
  23. Naganawa S., Yokoyama M., Shiino T., Suzuki T., Ishigatsubo Y., Ueda A., Shirai A., Takeno M., Hayakawa S., other authors. 2008; Net positive charge of HIV-1 CRF01_AE V3 sequence regulates viral sensitivity to humoral immunity. PLoS One 3:e3206 [View Article][PubMed]
     [Google Scholar]
  24. Nishimura Y., Shingai M., Willey R., Sadjadpour R., Lee W. R., Brown C. R., Brenchley J. M., Buckler-White A., Petros R., other authors. 2010; Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. J Virol 84:4769–4781 [View Article][PubMed]
     [Google Scholar]
  25. O'Brien W. A., Sumner-Smith M., Mao S.-H., Sadeghi S., Zhao J.-Q., Chen I. S. 1996; Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. J Virol 70:2825–2831[PubMed]
     [Google Scholar]
  26. O'Connell R. J., Kim J. H., Corey L., Michael N. L. 2012; Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med 2:a007351[PubMed] [CrossRef]
     [Google Scholar]
  27. O'Doherty U., Swiggard W. J., Malim M. H. 2000; Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 74:10074–10080 [View Article][PubMed]
     [Google Scholar]
  28. Otsuki H., Yoneda M., Igarashi T., Miura T. 2014; Generation of a monkey-tropic human immunodeficiency virus type 1 carrying env from a CCR5-tropic subtype C clinical isolate. Virology 460-461:1–10 [View Article][PubMed]
     [Google Scholar]
  29. Pitcher C. J., Hagen S. I., Walker J. M., Lum R., Mitchell B. L., Maino V. C., Axthelm M. K., Picker L. J. 2002; Development and homeostasis of T cell memory in rhesus macaque. J Immunol 168:29–43 [View Article][PubMed]
     [Google Scholar]
  30. Platt E. J., Wehrly K., Kuhmann S. E., Chesebro B., Kabat D. 1998; Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72:2855–2864[PubMed]
     [Google Scholar]
  31. Purtscher M., Trkola A., Gruber G., Buchacher A., Predl R., Steindl F., Tauer C., Berger R., Barrett N., other authors. 1994; A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 10:1651–1658 [View Article][PubMed]
     [Google Scholar]
  32. Rasheed M., Bettadapura R., Bajaj C. 2015; Computational refinement and validation protocol for proteins with large variable regions applied to model HIV Env spike in CD4 and 17b bound state. Structure 23:1138–1149 [View Article][PubMed]
     [Google Scholar]
  33. Reimann K. A., Li J. T., Veazey R., Halloran M., Park I.-W., Karlsson G. B., Sodroski J., Letvin N. L. 1996; A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 70:6922–6928[PubMed]
     [Google Scholar]
  34. Reimann K. A., Parker R. A., Seaman M. S., Beaudry K., Beddall M., Peterson L., Williams K. C., Veazey R. S., Montefiori D. C., other authors. 2005; Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J Virol 79:8878–8885 [View Article][PubMed]
     [Google Scholar]
  35. Repits J., Sterjovski J., Badia-Martinez D., Mild M., Gray L., Churchill M. J., Purcell D. F., Karlsson A., Albert J., other authors. 2008; Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology 379:125–134 [View Article][PubMed]
     [Google Scholar]
  36. Sadjadpour R., Theodore T. S., Igarashi T., Donau O. K., Plishka R. J., Buckler-White A., Martin M. A. 2004; Induction of disease by a molecularly cloned highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimera is multigenic. J Virol 78:5513–5519 [View Article][PubMed]
     [Google Scholar]
  37. Seaman M. S., Janes H., Hawkins N., Grandpre L. E., Devoy C., Giri A., Coffey R. T., Harris L., Wood B., other authors. 2010; Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84:1439–1452 [View Article][PubMed]
     [Google Scholar]
  38. Shibata R., Kawamura M., Sakai H., Hayami M., Ishimoto A., Adachi A. 1991; Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J Virol 65:3514–3520[PubMed]
     [Google Scholar]
  39. Shimizu Y., Okoba M., Yamazaki N., Goto Y., Miura T., Hayami M., Hoshino H., Haga T. 2006; Construction and in vitro characterization of a chimeric simian and human immunodeficiency virus with the RANTES gene. Microbes Infect 8:105–113 [View Article][PubMed]
     [Google Scholar]
  40. Shingai M., Donau O. K., Schmidt S. D., Gautam R., Plishka R. J., Buckler-White A., Sadjadpour R., Lee W. R., LaBranche C. C., other authors. 2012; Most rhesus macaques infected with the CCR5-tropic SHIVAD8 generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proc Natl Acad Sci U S A 109:19769–19774 [View Article][PubMed]
     [Google Scholar]
  41. Shingai M., Nishimura Y., Klein F., Mouquet H., Donau O. K., Plishka R., Buckler-White A., Seaman M., Piatak M. Jr., other authors. 2013; Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503:277–280[PubMed]
     [Google Scholar]
  42. Shinohara K., Sakai K., Ando S., Ami Y., Yoshino N., Takahashi E., Someya K., Suzaki Y., Nakasone T., other authors. 1999; A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey. J Gen Virol 80:1231–1240 [View Article][PubMed]
     [Google Scholar]
  43. Shioda T., Oka S., Ida S., Nokihara K., Toriyoshi H., Mori S., Takebe Y., Kimura S., Shimada K., other authors. 1994; A naturally occurring single basic amino acid substitution in the V3 region of the human immunodeficiency virus type 1 env protein alters the cellular host range and antigenic structure of the virus. J Virol 68:7689–7696[PubMed]
     [Google Scholar]
  44. Shiver J. W., Fu T.-M., Chen L., Casimiro D. R., Davies M.-E., Evans R. K., Zhang Z.-Q., Simon A. J., Trigona W. L., other authors. 2002; Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331–335 [View Article][PubMed]
     [Google Scholar]
  45. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., Katinger H. 2001; A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 17:1757–1765 [View Article][PubMed]
     [Google Scholar]
  46. Veazey R. S., DeMaria M., Chalifoux L. V., Shvetz D. E., Pauley D. R., Knight H. L., Rosenzweig M., Johnson R. P., Desrosiers R. C., Lackner A. A. 1998; Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280:427–431 [View Article][PubMed]
     [Google Scholar]
  47. Wang X., Rasmussen T., Pahar B., Poonia B., Alvarez X., Lackner A. A., Veazey R. S. 2007; Massive infection and loss of CD4+ T cells occurs in the intestinal tract of neonatal rhesus macaques in acute SIV infection. Blood 109:1174–1181 [View Article][PubMed]
     [Google Scholar]
  48. Wei X., Decker J. M., Liu H., Zhang Z., Arani R. B., Kilby J. M., Saag M. S., Wu X., Shaw G. M., Kappes J. C. 2002; Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46:1896–1905 [View Article][PubMed]
     [Google Scholar]
  49. Wei X., Decker J. M., Wang S., Hui H., Kappes J. C., Wu X., Salazar-Gonzalez J. F., Salazar M. G., Kilby J. M., other authors. 2003; Antibody neutralization and escape by HIV-1. Nature 422:307–312 [View Article][PubMed]
     [Google Scholar]
  50. Yuste E., Sanford H. B., Carmody J., Bixby J., Little S., Zwick M. B., Greenough T., Burton D. R., Richman D. D., other authors. 2006; Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol 80:3030–3041 [View Article][PubMed]
     [Google Scholar]
/content/journal/jgv/10.1099/jgv.0.000421
Loading
Generation of a neutralization-resistant CCR5 tropic simian/human immunodeficiency virus (SHIV-MK38) molecular clone, a derivative of SHIV-89.6
J. Gen. Virol. 97, 1249 (2016); https://doi.org/10.1099/jgv.0.000421
/content/journal/jgv/10.1099/jgv.0.000421
/content/journal/jgv/10.1099/jgv.0.000421
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error